Depending on tissue settings and genetic contents, Atox1 and CCS chaperones can control cisplatin trafficking routes and targeting efficiencies, thus indicating their essential contribution to acquired resistance of tumor cells to cisplatin-containing therapeutic regimens. The gene discussed is ATOX1; the disease is neoplasm.